Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 22, Issue 2, 1999, Pages 107-118

  Van Laethem, K ^a   Van Vaerenbergh, K ^a   Schmit, J C ^b   Sprecher, S ^c   Hermans, P ^d   De Vroey, V ^a   Schuurman, R ^e   Harrer, T ^f   Witvrouw, M ^a   Van Wijngaerden, E ^a   Stuyver, L ^g   Van Ranst, M ^a   Desmyter, J ^a   De Clercq, E ^a   Vandamme, A M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Retrovirology Laboratory Luxembourg   (Luxembourg)

^c PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

^d SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g INNOGENETICS   (Belgium)

Author keywords

Genotype; HIV 1 resistance; Phenotype; Sensitivity

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; LOVIRIDE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CASE REPORT; CONTROLLED STUDY; DNA PROBE; DNA TEMPLATE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032733696     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199910010-00001     Document Type: Article

References (28)

1. Vandamme A-M, Van Laethem K, De Clercq E. Managing resistance to anti-HIV drugs. Drugs 1999;57:337-61.
2. Schmit J-C, Cogniaux J, Hermans P, et al. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 1996;174:962-8.
3. Kellam P, Boucher CAB, Tijnagel JMGH, Larder BA. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994;75:341-51.
4. Wainberg MA, Lewis L, Salomon H, Gu Z, et al. Resistance to (-)-2′,3′-dideoxy-3′-thiacytidine (3TC) in HIV-1 isolated from paediatric patients. Antiviral Ther 1996;1:98-104.
5. Boucher CAB, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992;165:105-10.
6. Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991;5:137-44.
7. Shafer RW, Kozal MJ, Winters MA, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994;169:722-9.
8. Shirasaka T, Yarchoan R, O'Brien MC, et al. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci USA 1993; 90:562-6.
9. Schmit J-C, Van Laethem K, Ruiz L, et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998;12: 2005-15.
10. Stuyver L, Wyseur A, Rombout A, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997;284-91.
11. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-8.
12. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C, on behalf of the ENVA laboratories, the Sequencing Working Group, and participating laboratories. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 1999;37:2291-6.
13. Vandamme A-M, Witvrouw M, Pannecouque C, et al. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In Kinchington D, Schinazi RF. Methods in molecular medicine: antiviral methods and protocols. Totowa, NJ: The Humana Press, 1999.
14. Rodrigo AG, Goracke PC, Rowhanian K, Mullins JI. Quantification of target molecules from polymerase chain reaction based limiting dilution assays. AIDS Res Human Retroviruses 1997;13: 737-42.
15. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. J Immunol 1981;126:1614-19.
16. Vandamme A-M, Fransen K, Debaisieux L, et al. and the Belgian AIDS Reference Laboratories. Standardisation of primers and an algorithm for HIV-1 diagnostic PCR evaluated in patients harbouring strains of diverse geographical origin. J Virol Methods 1995; 51:305-16.
17. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hygiene 1938;27:493-7.
18. Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-21.
19. Durant J, Clevenbergh P, Halfon P, et al. Can HIV genotype determination be useful for individualized adaptation of antiretroviral therapy: the VIRADAPT French study [abstract OP7.1]. Presented at the 4th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 1998.
20. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696-9.
21. Myerhans A, Cheynier R, Albert J, et al. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 1989;58:901-10.
22. Kusumi K, Conway B, Cunningham S, et al. Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J Virol 1992;66:875-85.
23. Sabino E, Pan L-Z, Cheng-Mayer C, Mayer A. Comparison of in vivo plasma and peripheral blood mononuclear cell HIV-1 quasi-species to short-term tissue culture isolates: an analysis of tat and C2-V3 env regions. AIDS 1994;8:901-9.
24. von Briesen H, Grez M, Ruppach H, et al. Selection of HIV-1 genotypes by cultivation in different primary cells. AIDS 1999;13: 307-15.
25. Boyer PL, Hughes SH. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995;39:1624-8.
26. Back NKT, Nijhuis M, Keulen W, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996;15: 4040-9.
27. Garcia Lerma JG, Schinazi RF, Juodawlkis AS, et al. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC). Antimicrob Agents Chemother 1999;43:264-70.
28. Kaye S, Comber E, Tenant-Flowers M, Loveday C. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Human Retroviruses 1995;11:1221-5.